The effect of iodopovidone versus bleomycin in chemical pleurodesis.
Asian Cardiovasc Thorac Ann
; 26(5): 382-386, 2018 Jun.
Article
in En
| MEDLINE
| ID: mdl-29792037
ABSTRACT
Background Malignant pleural effusion continues to be a common problem in patients with metastatic disease. This study was conducted to compare the efficacy and safety of bleomycin pleurodesis with povidone-iodine pleurodesis through a chest drain as palliative treatment for recurrent malignant pleural effusion. Methods Sixty cancer patients (36 males and 24 females) with recurrent malignant pleural effusion were enrolled in a prospective randomized trial. Thirty patients received povidone-iodine pleurodesis and 30 received bleomycin pleurodesis. Age, sex, side of the primary pathology, treatment outcome (recurrence and relapse time), and complications were analyzed. Results The mean age was 59.63 ± 7.68 years in the povidone-iodine group and 57.97 ± 9.27 years in the bleomycin group ( p = 0.452). The complications were identical in both groups 2 (6.7%) patients had chest pain, 2 (6.7%) had fever, and one (3.3%) had hypotension. There was a good response to therapy in 20 (66.7%) patients in the bleomycin group and 25 (83.3%) in the povidone-iodine group ( p = 0.136). Conclusion The results of this study indicate that povidone-iodine should be considered as a selective chemical agent to perform pleurodesis in patients with recurrent malignant pleural effusion because it has the same effect but costs less than bleomycin.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Povidone-Iodine
/
Bleomycin
/
Pleural Effusion, Malignant
/
Pleurodesis
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Observational_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Asia
Language:
En
Journal:
Asian Cardiovasc Thorac Ann
Journal subject:
ANGIOLOGIA
/
CARDIOLOGIA
Year:
2018
Document type:
Article
Affiliation country:
Iran